Abstract library

20 results for "Erol".
#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia
Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Nicole Unger
Authors: Unger N, Theurer S, Herold T, Weber F, ...
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa
#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz
#315 The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Andrea Frilling
#417 CK19 Expression in A?TH-Producing Extrapituitary Neuroendocrine Neoplasms is a Negative Prognostic Factor
Introduction: Defining localization and potential ?CTH-producing extrapituitary neuroendocrine neoplasms (ACTH-epNEN) is important for clinical practice.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: I Voronkova
#1088 Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up
Introduction: Digestive Neuroendocrine Neoplasms (DNENs) express in 80% of cases somatostatin receptors (SSTRs) detected by functional imaging tests (FITs). FITs are needed at diagnosis to define therapy but their role in follow-up (FU) is unclear
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Elettra Merola
Authors: Merola E, Panzuto F, Capurso G, Kump P, ...
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#1232 Prognostic Role of FDG-PET in Advanced Digestive Neuroendocrine Neoplasms
Introduction: The role of FDG-PET to predict clinical outcome in advanced digestive neuroendocrine neoplasms (dNENs) is still unclear
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Doctor Maria Rinzivillo
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola